MNV
Market News Video
MNV MNV The 10 Most Popular Large-Caps in ETFs
MNV
MNV
MNV
MNV
MNV
MNV
MNV
Free Dividend Report - Top Ranked Stocks

Featured MNV Articles:

Accelerate Diagnostics Enters Oversold Territory (AXDX)
Friday, November 8, 12:01 PM ET, by Market News Video Staff

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy ...

Noteworthy Friday Option Activity: FLXN, AXDX, GPRO
Friday, November 8, 3:16 PM ET, by Market News Video Staff

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy ...

Noteworthy Monday Option Activity: AXDX, CBRL, MU
Monday, December 2, 3:20 PM ET, by Market News Video Staff

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume ...

Commit To Buy Accelerate Diagnostics At $12.50, Earn 25.3% Annualized Using Options
Wednesday, December 11, 11:59 AM ET, by Market News Video Staff

Investors eyeing a purchase of Accelerate Diagnostics Inc (AXDX) stock, but cautious about paying the ...

Noteworthy Wednesday Option Activity: AXDX, NLOK, AAP
Wednesday, December 11, 3:26 PM ET, by Market News Video Staff

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy ...

Snag This Deal Even Lower Than Director Strobeck Did

By Market News Video Staff, Monday, March 23, 10:26 AM ET
Play Video: One Reason For Insiders to Buy


If the video does not load after a few moments, Upgrade to the Latest Flash Player.

There's an old saying on Wall Street about insider buying: there are many possible reasons to sell a stock, but only one reason to buy. Back on March 18, Accelerate Diagnostics Inc's Director, Matthew Strobeck, invested $71,100.00 into 10,000 shares of AXDX, for a cost per share of $7.11. Bargain hunters tend to pay particular attention to insider buys like this one, because presumably the only reason an insider would take their hard-earned cash and use it to buy stock of their company in the open market, is that they expect to make money.

In trading on Monday, bargain hunters could buy shares of Accelerate Diagnostics Inc (NASDAQ:AXDX) and achieve a cost basis 33.2% cheaper than Strobeck, with shares changing hands as low as $4.75 per share. Accelerate Diagnostics Inc shares are currently trading up about 5.7% on the day. The chart below shows the one year performance of AXDX shares, versus its 200 day moving average:

Accelerate Diagnostics Inc Chart

Looking at the chart above, AXDX's low point in its 52 week range is $4.53 per share, with $24 as the 52 week high point — that compares with a last trade of $4.89. By comparison, below is a table showing the prices at which AXDX insider buying was recorded over the last six months:

Purchased Insider Title Shares Price/Share Value
03/18/2020 Matthew Strobeck Director 10,000 $7.11 $71,100.00

Special Offer: Receive our best dividend ideas directly to your inbox each afternoon with the Dividend Channel Premium Newsletter


This Article's Word Cloud:   AXDX   Accelerate   Back   Bargain   Bargains   Channel   Cheaper   Diagnostics   Director   Dividend   Insider   Insiders   Looking   March   Matthew   Monday   Newsletter   Offer   Premium   Price   Purchased   Receive   Share   Shares   Special   Start   Street   Strobeck   Than   There   Title   about   below   buying   chart   cost   hunters   insider   last   only   point   reason   share   shares   stock   that   their   trading   week   with
MNV
MNV
About Us - Advertise - Contact Us - Embedding Videos - Licensing Videos - Partners - mRSS / RSS Feed - Terms of Use - Privacy Policy
MNV
Home  |  Analyst News  Dividend Report  ETFs  Insider Report  Large Caps  Market Movers  Week Ahead Report  Weekly Market Wrap
MNV
MNV MNV Stock Message Boards Stock Market Definitions
MNV

Snag This Deal Even Lower Than Director Strobeck Did | Market News Video | Copyright © 2008 - 2020, All Rights Reserved

Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners. In no way should any content contained herein be interpreted to represent trading or investment advice. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.